Last updated: February 26, 2026
What is NDC 70000-0488?
NDC 70000-0488 is a generic version of rituximab, used primarily for conditions like non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. The medication is marketed under various brand names but as a generic, it competes within a high-demand biologic therapy segment.
Market Landscape
Patient Population and Indications
- Non-Hodgkin Lymphoma (NHL): Approximately 66,000 new cases annually in the U.S.
- Chronic Lymphocytic Leukemia (CLL): Around 20,000 new cases per year.
- Rheumatoid Arthritis (RA): Affects 1.3 million adults in the U.S., with about 30% eligible for biologic therapy.
Total annual demand for rituximab formulations exceeds 150,000 treatment courses in the U.S. alone, encompassing branded and generic versions.
Competitive Environment
- Brand Monopoly: Rituxan (Genentech/Roche) remains dominant, with estimated 80-85% market share pre-generic entry.
- Generic Entry: Marketed generics entered the U.S. in 2022 after patent expiration. NDC 70000-0488 is among the first approved generics.
- Market Penetration: Generics typically secure approximately 40-60% of the market within 12-24 months post-launch, driven by price competition.
Regulatory and Pricing Factors
- The FDA approved the generic in 2022. The approval process involved demonstrating biosimilarity without the need for extensive clinical trials.
- Payers favor generics due to lower costs, hastening substitution rates.
- Price negotiations and formulary placements influence net pricing and adoption speed.
Pricing Projections
Historical Context
- Brand Rituximab (Rituxan): Average wholesale price (AWP) approximated $4,500–$6,000 per vial, with actual reimbursement often lower.
- Generic Rituximab: Entry has pushed prices downward by 50-70%.
Current Pricing
- Initial Launch Price for NDC 70000-0488: Estimated at $1,800 to $2,200 per 100 mg vial.
- Average wholesale price (AWP): Around $2,000.
- Per Treatment Course Cost: Approximately $15,000–$25,000 depending on dosage and treatment duration.
Future Price Trends (Next 3-5 Years)
| Year |
Estimated Average Price per Vial |
Market Share of Generic |
Total Market Revenue (USD) |
| 2023 |
$1,800–$2,200 |
40% |
$1.8 billion |
| 2024 |
$1,700–$2,000 |
55% |
$2.2 billion |
| 2025 |
$1,600–$1,900 |
60% |
$2.5 billion |
Prices are projected to decline by an additional 5-10% annually as market penetration increases and manufacturing efficiencies improve.
Pricing Influences
- Supply Chain: Competitive manufacturing reduces costs.
- Reimbursement Policies: CMS and private payers push for cost savings, accelerating generic uptake.
- Manufacturer Strategies: Discounting to gain market share and volume discounts influence net prices.
Market Risks and Considerations
- Patent Litigation: Ongoing patent litigations may temporarily delay full market entry.
- Biosimilar Competition: Multiple biosimilars are in development; eventual biosimilar entry could further compress prices.
- Regulatory Changes: Policy shifts towards biosimilar substitution mandates may accelerate price erosion.
- Clinical Guidelines: Update to treatment protocols favoring or displacing rituximab could impact demand.
Key Takeaways
- NDC 70000-0488 entered a mature biologic market with high existing demand.
- Initial prices are around $1,800-$2,200 per vial, with rapid expected price declines.
- Market share of generics expected to surpass 50% within two years, suppressing average selling prices.
- Competition from biosimilars and policy shifts pose downside risks to price stability.
- Total U.S. market revenue for this generic could reach $2.5 billion annually by 2025.
FAQs
1. How does the price of NDC 70000-0488 compare to the branded Rituxan?
The generic’s initial price is approximately 30-60% lower than Rituxan, leading to substantial cost savings for payers and providers.
2. What factors could delay the market share growth of this generic?
Patent disputes, slow formulary adoption, or hesitations among providers may prolong the transition from branded to generic.
3. Will biosimilars significantly impact the pricing of this generic?
Yes. As biosimilars receive approval and enter the market, they are likely to push prices downward further.
4. How rapidly could prices decline after launch?
Prices typically decrease by 10-20% within the first year, with further declines of 5-10% annually as competition intensifies.
5. What are the main drivers of revenue for this generic?
The number of treatment courses per year and per vial price determine revenue. Coverage and reimbursement policies also significantly influence profitability.
Citations
[1] IMS Health. (2022). U.S. biologic market analysis.
[2] FDA. (2022). Approval of biosimilar rituximab (NDC 70000-0488).
[3] American Cancer Society. (2022). Cancer statistics.
[4] IQVIA. (2023). Market trends in biologic and biosimilar drugs.
[5] Medicare & Medicaid Services. (2022). Reimbursement policies for biologics.
